September 2026

Join WhatsApp Channel 

GPAT caoching
Macleods Walk in Drive for Production Department
30 September 2026

Macleods Walk in Drive for Production Department

Macleods is one of the fastest growing pharmaceutical company, having strong presence in various therapeutics segments. Ranked amongst the top 10 companies.
Work as GPV Professional at Teva - MPharm, PharmD, BPharm Apply
30 September 2026
Work as GPV Professional at Teva - MPharm, PharmD, BPharm Apply
Basic knowledge on TEVA product portfolio, their therapeutic areas expertise, mechanism of actions and its product/patient safety index.
Sri Krishna Hiring for R&D Formulation - M.Pharm freshers can also apply
30 September 2026
Sri Krishna Hiring for R&D Formulation - M.Pharm freshers can also apply
Conduct laboratory trials and formulation/process evaluation. Support aseptic processing and sterile manufacturing development. Evaluate formulation parameters and excipient compatibility.
Medgel Private Limited is looking for candidates in Quality Assurance Department
30 September 2026
Medgel Private Limited is looking for candidates in Quality Assurance Department

Medgel Private Limited is looking for candidates for the Quality Assurance Department.

WALK-IN & TELEPHONIC INTERVIEW

Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal
30 September 2026
Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal

Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited to acquire its Wellness Portfolio, in a transaction that could have a total consideration of up to ₹46.7 crore.

According to the company’s regulatory disclosure dated September 23, 2026, the acquisition will be undertaken on a going-concern basis through a slump sale. Jagsonpal said the move is aimed at strengthening its pharmaceutical portfolio, expanding its presence across relevant therapeutic segments and increasing its market reach.

Foundayo Shows Greater Weight Loss and A1C Reduction Than Oral Semaglutide
30 September 2026
Foundayo Shows Greater Weight Loss and A1C Reduction Than Oral Semaglutide
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.
Ozempic Linked to Lower Cardiovascular Risk Than Mounjaro in Type 2 Diabetes
30 September 2026
Ozempic Linked to Lower Cardiovascular Risk Than Mounjaro in Type 2 Diabetes
Novo Nordisk today announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg.
6th National Pharmacovigilance Week 2026 at Saveetha College of Pharmacy
30 September 2026
6th National Pharmacovigilance Week 2026 at Saveetha College of Pharmacy

In observance of the 6th National Pharmacovigilance Week 2026, the Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, in collaboration with the Indian Pharmaceutical Association – Hospital Pharmacy Division (IPA-HPD), organized a series of awareness and educational programmes from September 17 to 23, 2026.

DTAB Recommends Separate GMP Requirements for Clinical and Non-Clinical Drug Manufacturing
30 September 2026
DTAB Recommends Separate GMP Requirements for Clinical and Non-Clinical Drug Manufacturing
The Drugs Technical Advisory Board, DTAB, has recommended changes to the regulatory requirements for manufacturing drugs intended for clinical trials, bioavailability and bioequivalence studies, analytical testing and non-clinical studies.
Novo Nordisk vs Eli Lilly: Semaglutide, Tirzepatide and Orforglipron - Why Recent Comparative Data Tell Different Stories
30 September 2026
Novo Nordisk vs Eli Lilly: Semaglutide, Tirzepatide and Orforglipron - Why Recent Comparative Data Tell Different Stories
The competition between Novo Nordisk and Eli Lilly in the diabetes and obesity medicine market is producing a new wave of comparative clinical data. In September 2026, both companies released analyses comparing their medicines with competing therapies, but the results are not all pointing in the same direction.